IMPAIRMENT OF RENAL FUNCTION IN PATIENTS ON 1$alpha;-HYDROXYCHOLECALCIFEROL

Winterborn, M H; Mace, P. J. E.; Heath, David A.; White, Richard

doi:10.1016/s0140-6736(78)91530-1

Cited by 29 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CKD progression is another potentially harmful side effect of active vitamin D treatment [ 22 ]. Trials using calcitriol at a dose of 0.5–1.0 μg/day reported an increase in serum creatinine levels compared with placebo groups, both in patients with normal baseline renal function and in those with pre-existing renal impairment [ 23 – 26 ].…”

Section: Discussionmentioning

confidence: 99%

Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study

Hadjiyannakos

Filiopoulos

Trompouki

et al. 2013

Clinical Kidney Journal

View full text Add to dashboard Cite

BackgroundActive vitamin D is an effective treatment for secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients often complicated by hypercalcaemia and hyperphosphataemia. Treatment with paricalcitol, a selective vitamin D receptor activator, has shown benefits by adequately reducing parathyroid hormone (PTH) levels with minimal changes in serum calcium (Ca) and phosphorus (P). The purpose of this study is to present data on the use of oral paricalcitol in real-life clinical practice in patients with CKD stage 3–4 and SHPT.MethodsWe studied 43 patients, M/F: 25/18, median age: 74 years (47–87), CKD stage 3/4: 16/27, with SHPT, who were prescribed oral paricalcitol at recommended doses for 6 months. Monthly measurements of serum intact PTH (iPTH), Ca, P, alkaline phosphatase (ALP), haemoglobin, albumin (ALB), lipid profile, proteinuria and 24-h urine creatinine clearance were performed 3 months before and 6 months after treatment initiation.ResultsParicalcitol induced a significant, early and sustained, through the end of follow-up period, decrease in iPTH and ALP levels and an increase in serum ALB. No significant increase in Ca and P levels as well as in Ca × P product was observed during the study period. No significant changes were found in protein excretion, kidney function and the other measured parameters between baseline and last evaluation. Paricalcitol final median dose was 5 μg/week ranging between 3 and 7 μg/week.ConclusionsIn the context of real-life clinical practice, oral paricalcitol for 6 months is an effective, well-tolerated treatment of SHPT in CKD stage 3–4 with minimal effects on calcium and phosphorus metabolism.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study

Hadjiyannakos

Filiopoulos

Trompouki

et al. 2013

Clinical Kidney Journal

View full text Add to dashboard Cite

show abstract

“…Unfortunately the rise of the serum calcium is often accompanied by a rise of inorganic serum phosphorus with an increase of their combination product and calcification in soft tissues, including the kidney, with a subsequent further function deterioration [Mflisryet al, 1980;Winterburn et al, 1978;Winklers t al., 1978;Nordin, 1978;Christiansen et al. 1979], Though less documented, the mere administration of 1,25(0^20^ and l(OH)D, are suspected to be deleterious to renal function even when the C'axP product is not increased [Christiansen el al., 1978;Muhtadieet al, 1983].…”

Section: Mistakes In the Selection O F Patients In Dietary Restrictimentioning

confidence: 99%

Dietary Treatment of Chronic Renal Failure: Why Is It Not Used More Frequently?

Giovannetti

1985

Nephron

View full text Add to dashboard Cite

“…On this basis, patients were divided into those in whom glomerular function remained stable (No. 1-10, table I), and patients in whom plasma creatinine rose significantly during treatment (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). In these latter patients, the rate of rise of plasma creatinine was assessed both before and during treatment.…”

Section: Methodsmentioning

confidence: 99%

Effects of Vitamin D Metabolites and Analogues on Renal Function

Naik

Cundy

Robinson

et al. 1981

Nephron

View full text Add to dashboard Cite

The long-term effects of vitamin D analogues and metabolites on renal function were assessed in 24 patients with and without chronic renal failure. Treatment for periods of 5–45 months did not adversely affect renal function in 10 of 11 patients with stable renal function, although transient hypercalcaemia did cause transient rises in plasma creatinine. Of 13 patients with progressive renal failure before treatment, vitamin D-like compounds or the vehicle used for their administration may have accelerated renal failure in 3 patients independently of changes in plasma calcium or phosphate. Particular difficulties in assessing the effects of vitamin D-like compounds in progressive renal disease are discussed.

show abstract

IMPAIRMENT OF RENAL FUNCTION IN PATIENTS ON 1$alpha;-HYDROXYCHOLECALCIFEROL

Cited by 29 publications

References 0 publications

Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study

Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study

Dietary Treatment of Chronic Renal Failure: Why Is It Not Used More Frequently?

Effects of Vitamin D Metabolites and Analogues on Renal Function

Contact Info

Product

Resources

About